Follow
piero pollesello
piero pollesello
Orion Pharma
Verified email at orionpharma.com
Title
Cited by
Cited by
Year
Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis
R Longo, P Pollesello, C Ricci, F Masutti, BJ Kvam, L Bercich, LS Croce, ...
Journal of Magnetic Resonance Imaging 5 (3), 281-285, 1995
4871995
Noninvasive in vivo quantitative assessment of fat content in human liver
C Ricci, R Longo, E Gioulis, M Bosco, P Pollesello, F Masutti, LS Crocè, ...
Journal of hepatology 27 (1), 108-113, 1997
3971997
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan
Z Papp, I Édes, S Fruhwald, SG De Hert, M Salmenperä, H Leppikangas, ...
International journal of cardiology 159 (2), 82-87, 2012
3762012
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.
P Pollesello, M Ovaska, J Kaivola, C Tilgmann, K Lundström, N Kalkkinen, ...
Journal of Biological Chemistry 269 (46), 28584-28590, 1994
3081994
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure …
RA de Boer, G De Keulenaer, J Bauersachs, D Brutsaert, JG Cleland, ...
European journal of heart failure 21 (3), 272-285, 2019
2472019
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure …
C Maack, M Lehrke, J Backs, FR Heinzel, JS Hulot, N Marx, WJ Paulus, ...
European heart journal 39 (48), 4243-4254, 2018
2402018
Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels
P Kaheinen, P Pollesello, J Levijoki, H Haikala
Journal of cardiovascular pharmacology 37 (4), 367-374, 2001
2382001
Levosimendan: current data, clinical use and future development
MS Nieminen, S Fruhwald, LMA Heunks, PK Suominen, AC Gordon, ...
Heart, lung and vessels 5 (4), 227, 2013
2142013
The patient perspective: quality of life in advanced heart failure with frequent hospitalisations
MS Nieminen, K Dickstein, C Fonseca, JM Serrano, J Parissis, F Fedele, ...
International journal of cardiology 191, 256-264, 2015
1972015
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C
T Sorsa, S Heikkinen, MB Abbott, E Abusamhadneh, T Laakso, ...
Journal of biological chemistry 276 (12), 9337-9343, 2001
1872001
Pharmacological mechanisms contributing to the clinical efficacy of levosimendan
Z Papp, K Csapó, P Pollesello, H Haikala, I Édes
Cardiovascular drug reviews 23 (1), 71-98, 2005
1852005
Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca2+-binding glycoprotein.
B de Bernard, P Bianco, E Bonucci, M Costantini, GC Lunazzi, ...
The Journal of cell biology 103 (4), 1615-1623, 1986
1841986
Levosimendan is a mitochondrial KATP channel opener
DM Kopustinskiene, P Pollesello, NEL Saris
European journal of pharmacology 428 (3), 311-314, 2001
1832001
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig
S Szilágyi, P Pollesello, J Levijoki, P Kaheinen, H Haikala, I Édes, Z Papp
European journal of pharmacology 486 (1), 67-74, 2004
1662004
A role for the RISK pathway and KATP channels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heart
EF Du Toit, A Genis, LH Opie, P Pollesello, A Lochner
British journal of pharmacology 154 (1), 41-50, 2008
1632008
Potassium-specific effects of levosimendan on heart mitochondria
DM Kopustinskiene, P Pollesello, NEL Saris
Biochemical pharmacology 68 (5), 807-812, 2004
1592004
The cardioprotective effects of levosimendan: preclinical and clinical evidence
P Pollesello, Z Papp
Journal of cardiovascular pharmacology 50 (3), 257-263, 2007
1532007
Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion
W Toller, M Heringlake, F Guarracino, L Algotsson, J Alvarez, ...
International Journal of Cardiology 184, 323-336, 2015
1412015
Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper
D Farmakis, J Alvarez, TB Gal, D Brito, F Fedele, C Fonseca, AC Gordon, ...
International Journal of Cardiology 222, 303-312, 2016
1402016
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c
T Sorsa, P Pollesello, RJ Solaro
Molecular and cellular biochemistry 266, 87-107, 2004
1392004
The system can't perform the operation now. Try again later.
Articles 1–20